- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06803771
Nadzór zdrowia trzustki po diagnozie cukrzycy (SAFE-D)
An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.
Participants will:
- attend 3 study visits over 12 months time
- provide a blood sample at each study visit
- complete an anxiety questionnaire at each visit.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival.
There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage.
People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing.
The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years.
Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: SAFE-D Trial Manager
- Numer telefonu: +442381205154
- E-mail: safed@soton.ac.uk
Lokalizacje studiów
-
-
-
Ashton-under-Lyne, Zjednoczone Królestwo, OL6 6HD
- Aktywny, nie rekrutujący
- Ashton Medical Group
-
Birmingham, Zjednoczone Królestwo, B14 4DU
- Rekrutacyjny
- Yardley Wood Health Centre
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Bournemouth, Zjednoczone Królestwo, BH7 7DW
- Aktywny, nie rekrutujący
- Bournemouth Research Hub
-
Bromborough, Zjednoczone Królestwo, CH62 6EE
- Rekrutacyjny
- Eastham Group Practice
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Zjednoczone Królestwo, NW10 2PT
- Rekrutacyjny
- Willesden Medical Centre
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Zjednoczone Królestwo, SW1P 2PF
- Rekrutacyjny
- South Westminster Centre
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Zjednoczone Królestwo, W7 1DR
- Rekrutacyjny
- The Cuckoo Lane Practice
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Manchester, Zjednoczone Królestwo, M14 6WP
- Aktywny, nie rekrutujący
- Bodey Medical Centre
-
Manchester, Zjednoczone Królestwo, M23 1JX
- Aktywny, nie rekrutujący
- Bowland Medical Practice
-
Manchester, Zjednoczone Królestwo, M23 2SY
- Aktywny, nie rekrutujący
- The Maples Medical Centre
-
Nottingham, Zjednoczone Królestwo, NG17 4JL
- Rekrutacyjny
- King's Mill Hospital (Sherwood Forest) Research Van
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Portsmouth, Zjednoczone Królestwo, PO1 3HN
- Aktywny, nie rekrutujący
- Portsmouth Research Hub
-
Rossendale, Zjednoczone Królestwo, BB4 5SL
- Rekrutacyjny
- Hazelvalley Family Practice
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Ruislip, Zjednoczone Królestwo, HA4 8NX
- Rekrutacyjny
- Pembroke Centre (Hillingdon)
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Southampton, Zjednoczone Królestwo, SO30 3JB
- Rekrutacyjny
- Moorgreen Hospital
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Southampton, Zjednoczone Królestwo, SO15 33UA
- Aktywny, nie rekrutujący
- Southampton Research Hub (Shirley Research Hub)
-
Uttoxeter, Zjednoczone Królestwo, ST14 8JG
- Rekrutacyjny
- Balance Street Health Centre
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Uxbridge, Zjednoczone Królestwo, UB8 1UW
- Rekrutacyjny
- Civic Centre
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Walsall, Zjednoczone Królestwo, WS6 6EW
- Rekrutacyjny
- Quinton Practice
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Weymouth, Zjednoczone Królestwo, DT4 0QE
- Aktywny, nie rekrutujący
- Weymouth Research Hub
-
-
Cheshire
-
Sandbach, Cheshire, Zjednoczone Królestwo, CW11 1EQ
- Aktywny, nie rekrutujący
- Ashfields Primary Care Centre
-
-
Kent
-
Maidstone, Kent, Zjednoczone Królestwo, ME16 9QQ
- Rekrutacyjny
- Maidstone and Tunbridge Wells NHS Trust
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Leicester Forest East
-
Leicester, Leicester Forest East, Zjednoczone Królestwo, LE3 3LW
- Rekrutacyjny
- Forest Medical Group
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Leicestershire
-
Kibworth Beauchamp, Leicestershire, Zjednoczone Królestwo, LE8 0LG
- Rekrutacyjny
- South Leicestershire Medical Group
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Staffordshire
-
Burton-on-Trent, Staffordshire, Zjednoczone Królestwo, DE14 3RH
- Rekrutacyjny
- Peel Croft Surgery
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Kingswinford, Staffordshire, Zjednoczone Królestwo, DY6 8DN
- Rekrutacyjny
- Kingswinford Medical Practice
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Leek, Staffordshire, Zjednoczone Królestwo, ST13 6QR
- Rekrutacyjny
- Park Medical Centre
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Stratford-upon-Avon, Staffordshire, Zjednoczone Królestwo, CV37 6HJ
- Rekrutacyjny
- Trinity Court Surgery
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Surrey
-
Brockham, Surrey, Zjednoczone Królestwo, RH3 7NJ
- Rekrutacyjny
- Brockwood Medical Practice
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Epsom, Surrey, Zjednoczone Królestwo, KT17 4BL
- Rekrutacyjny
- Integrated Care Partnership/ The Old Cottage Hospital
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
Warlingham, Surrey, Zjednoczone Królestwo, CR6 9NW
- Rekrutacyjny
- Warlingham Green Medical Practice
-
Kontakt:
- Anson-Wisniewska
- Numer telefonu: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
- Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
- Willing to provide up to 30 mL of blood for each study visit
- Willing and eligible to undergo MRI or CT scan
- Understands the study process and is willing to take part in the study and sign the informed consent form
Exclusion Criteria:
- Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.
- A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
- Under investigation for or confirmed pancreatic cancer
- Under investigation/surveillance for pancreatic cyst
- Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
- Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
- BMI > 40 at the time of consent
- Blood transfusion within 1 month
- Solid organ transplant recipient
- Currently pregnant
- Needing dialysis
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Diagnostyczny
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Interventional
Participants will have their blood samples tested on the Avantect test within prioritised timeframe. The "detected" Avantect test results will be shared with the participants and their General Practitioners (GPs) to allow for further MRI or CT investigations by the local clinical team. |
Avantect test |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Sensitivity of the Avantect test
Ramy czasowe: The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "detected" test result who have pancreatic cancer diagnosed via imaging in relation to all individuals in the study who had pancreatic cancer diagnosed. |
The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
|
Specificity of the Avantect test
Ramy czasowe: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "not detected" test results, and no Avantect "detected" results, who did not have a pancreatic cancer diagnosis in relation to all individuals in the study who did not have a pancreatic cancer diagnosis. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Stage shift
Ramy czasowe: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of pancreatic cancers cases diagnosed at stage I/II out of all participants diagnosed with pancreatic cancer between SAFE-D participants and point-estimate of the proportion from comparative data. Stage shift will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Positive Predictive Value (PPV) of Avantect test in detecting pancreatic cancer (PC)
Ramy czasowe: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with an Avantect "detected" result who have pancreatic cancer diagnosed. The analysis will be conducted with a sample size of 5,000, pancreatic cancer prevalence of 0.8%, and 5% lost from the per protocol population. There will be an expected 261 individuals with an Avantect "detected" result. 9.6% (25/261) are expected to have a PC. PPV will be considered successful if a null PPV of 5% can be ruled out at a one-sided p-value of 0.05. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Negative Predictive Value (NPV) of Avantect test in ruling out pancreatic cancer (PC)
Ramy czasowe: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
With a sample size of 5,000, PC prevalence of 0.8%, and 5% lost from the per protocol population, there will be an expected 4,489 individuals without an Avantect "detected" result. 99.6% (4,476/4,489) are expected to not have a diagnosis of PC. NPV will be considered successful if a null NPV of 99% can be ruled out at a one-sided p-value of 0.05. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resection rate of pancreatic cancer
Ramy czasowe: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with pancreatic cancer who underwent resection. The analysis will be conducted by comparing the proportion of pancreati cancer cases that underwent resection as a treatment modality between SAFE-D participants and the point-estimate of the proportion from comparative data. Resection rate will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resectability
Ramy czasowe: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of pancreatic cancers deemed resectable by the study MDST. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Time-to-event outcomes
Ramy czasowe: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the time from new onset diabetes diagnosis to pancreatic cancer diagnosis. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Overall survival
Ramy czasowe: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the overall survival of study participants. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Effect of the Avantect test on state anxiety over time
Ramy czasowe: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To assess the effect of the Avantect test on state anxiety over time. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
High-grade neoplasia
Ramy czasowe: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To investigate the performance characteristics for high-grade neoplasia. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Współpracownicy i badacze
Współpracownicy
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu hormonalnego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby metaboliczne
- Nowotwory Układu Pokarmowego
- Choroby Układu Pokarmowego
- Zaburzenia metabolizmu glukozy
- Nowotwory gruczołów dokrewnych
- Choroby trzustki
- Choroby żywieniowe i metaboliczne
- Cukrzyca typu 2
- Nowotwory trzustki
- Cukrzyca
- Rak trzustki, dorosły
Inne numery identyfikacyjne badania
- RHMGSU0292
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .